IP Library Granted Patent US 7,084,242
Granted Patent B2
US 7,084,242 · App. 10/236,903 · Granted Aug 1, 2006

DNA molecule encoding a mutant prepro-neuropeptide Y, a mutant signal peptide, and uses thereof

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,084,242
App. No.
10/236,903
Granted
Aug 1, 2006
Kind
B2
Abstract

The invention relates to a DNA sequence comprising a nucleotide sequence encoding a prepro-neuropeptide Y (preproNPY) where the leucine amino acid in position 7 of the signal peptide part of said preproNPY has been replaced by proline. The invention concerns further the mutant signal peptide or the mutant signal peptide associated with any other cleavage product of preproNPY, methods for the determination, in a biological sample, of the DNA sequence or the peptide. Furthermore, this invention relates to a method for diagnosing a predisposition for increased serum cholesterol or LDL cholesterol level in a human subject, and to methods for treating a human subject diagnosed for predisposition for increased serum cholesterol or LDL cholesterol. The present invention also relates to transgenic animals carrying either the mutant sequence or the normal sequence.

Claims (2)

1. A signal peptide of preproNPY consisting of amino acid residues 1–28 of SEQ ID NO:6 having the leucine in the 7 position replaced by proline.

2. A peptide comprising the signal peptide of claim 1 associated with any other cleavage product of preproNPY.

Assignments (2)
SECURITY AGREEMENT Recorded Apr 24, 2009
From: QUATRX PHARMACEUTICALS COMPANY
To: HERCULES TECHNOLOGY GROWTH CAPITAL, INC.
Reel/Frame 022584/0669 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 5, 2006
From: HORMOS MEDICAL CORPORATION
To: PHASE ONE PHARMA OY LTD.
Reel/Frame 018353/0633 →